These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27830380)

  • 41. Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy.
    Tanabe Y; Nagayama K; Enomoto N; Izumi N; Tazawa J; Kurosaki M; Sakamoto N; Sato C; Watanabe M
    J Viral Hepat; 2005 May; 12(3):251-61. PubMed ID: 15850465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
    Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
    J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
    Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.
    Kanda T; Imazeki F; Yonemitsu Y; Mikami S; Takada N; Nishino T; Takashi M; Tsubota A; Kato K; Sugiura N; Tawada A; Wu S; Tanaka T; Nakamoto S; Mikata R; Tada M; Chiba T; Kurihara T; Arai M; Fujiwara K; Kanai F; Yokosuka O
    J Viral Hepat; 2011 Jul; 18(7):e292-7. PubMed ID: 21129130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C].
    Husa P; Slesinger P; Stroblová H; Svobodník A
    Vnitr Lek; 2006 Feb; 52(2):153-9. PubMed ID: 16623278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
    J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
    Basso M; Giannini EG; Torre F; Blanchi S; Savarino V; Picciotto A
    Hepatology; 2009 May; 49(5):1442-8. PubMed ID: 19350657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted Metabolomics Identifies Differential Serum and Liver Amino Acids Biomarkers in Rats with Alcoholic Liver Disease.
    Shi C; Wang L; Zhou K; Shao M; Lu Y; Wu T
    J Nutr Sci Vitaminol (Tokyo); 2020; 66(6):536-544. PubMed ID: 33390395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Specific changes in amino acid profiles in monocytes of patients with breast, lung, colorectal and ovarian cancers.
    Chagovets V; Starodubtseva N; Tokareva A; Novoselova A; Patysheva M; Larionova I; Prostakishina E; Rakina M; Kazakova A; Topolnitskiy E; Shefer N; Kzhyshkowska J; Frankevich V; Sukhikh G
    Front Immunol; 2023; 14():1332043. PubMed ID: 38259478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of Plasma Amino Acid Dynamics in Response to ACTH Stimulation by Liquid Chromatography Tandem-Mass Spectrometry.
    Paal M; Lindner JM; Schmoeckel P; Suhr AC; Schafferer S; Koal T; Briegel J; Vogeser M
    Clin Lab; 2018 Oct; 64(10):1695-1700. PubMed ID: 30336519
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics.
    Kus K; Kij A; Zakrzewska A; Jasztal A; Stojak M; Walczak M; Chlopicki S
    Breast Cancer Res; 2018 Dec; 20(1):148. PubMed ID: 30514398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The metabolic fingerprint of chronic hepatitis C progression: Metabolome shifts and cutting-edge diagnostic options.
    Deep A; Swaroop S; Dubey D; Rawat A; Verma A; Baisya B; Parihar R; Goel A; Rungta S
    J Mol Recognit; 2024 Jan; 37(1):e3066. PubMed ID: 37916582
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of mass spectrometry-based relatively quantitative targeted method for amino acids and neurotransmitters: Applications in the diagnosis of major depression.
    Chen H; Xie H; Huang S; Xiao T; Wang Z; Ni X; Deng S; Lu H; Hu J; Li L; Wen Y; Shang D
    J Pharm Biomed Anal; 2021 Feb; 194():113773. PubMed ID: 33279298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted metabolomics profiling in pregnancy associated with vitamin D deficiency.
    Li X; An Z; Yao A; Li R; Zhang S; Yu S; Ma L; Liu Y
    BMC Pregnancy Childbirth; 2024 Apr; 24(1):295. PubMed ID: 38643102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study.
    Cao B; Wang D; Brietzke E; McIntyre RS; Pan Z; Cha D; Rosenblat JD; Zuckerman H; Liu Y; Xie Q; Wang J
    Amino Acids; 2018 Aug; 50(8):1013-1023. PubMed ID: 29796929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.